首页> 外文期刊>Journal of pharmaceutical sciences. >Future Supply Chains Enabled by Continuous Processing-Opportunities and Challenges May 20-21, 2014 Continuous Manufacturing Symposium
【24h】

Future Supply Chains Enabled by Continuous Processing-Opportunities and Challenges May 20-21, 2014 Continuous Manufacturing Symposium

机译:未来的供应链通过连续加工 - 机会和挑战,2014年5月20日至21日持续制造研讨会

获取原文
获取原文并翻译 | 示例
           

摘要

This paper examines the opportunities and challenges facing the pharmaceutical industry in moving to a primarily continuous processing-based supply chain. The current predominantly large batch and centralized manufacturing system designed for the blockbuster drug has driven a slow-paced, inventory heavy operating model that is increasingly regarded as inflexible and unsustainable. Indeed, new markets and the rapidly evolving technology landscape will drive more product variety, shorter product life-cycles, and smaller drug volumes, which will exacerbate an already unsustainable economic model. Future supply chains will be required to enhance affordability and availability for patients and healthcare providers alike despite the increased product complexity. In this more challenging supply scenario, we examine the potential for a more pull driven, near real-time demand-based supply chain, utilizing continuous processing where appropriate as a key element of a more flow-through operating model. In this discussion paper on future supply chain models underpinned by developments in the continuous manufacture of pharmaceuticals, we have set out; The significant opportunities to moving to a supply chain flow-through operating model, with substantial opportunities in inventory reduction, lead-time to patient, and radically different product assurance/stability regimes. Scenarios for decentralized production models producing a greater variety of products with enhanced volume flexibility. Production, supply, and value chain footprints that are radically different from today's monolithic and centralized batch manufacturing operations. Clinical trial and drug product development cost savings that support more rapid scale-up and market entry models with early involvement of SC designers within New Product Development. The major supply chain and industrial transformational challenges that need to be addressed.
机译:本文探讨了制药行业迁移到主要连续加工的供应链的机遇和挑战。目前主要为大磅药物设计的大型批量和集中制造系统已经推动了缓慢的库存重型操作模型,越来越多地被视为不灵活和不可持续的。实际上,新的市场和快速发展的技术景观将推动更多的产品种类,更短的产品寿命,以及更小的药物体积,这将加剧已经不可持续的经济模式。尽管产品复杂性提高,将需要未来的供应链以提高患者和医疗保健提供者的可负担性和可用性。在这种更具挑战性的供应方案中,我们在基于实时需求的供应链附近,使用连续处理的更具拉动驱动的可能性,以适当作为更流通操作模型的关键元件。在本讨论中,有关未来供应链模型的未来供应链模型,在不断制造药品的发展中,我们已经掀起了;迁移到供应链流通运营模式的重要机会,具有大量机会在库存减少,患者的报告时间和彻底不同的产品保证/稳定性制度。分散生产模型的场景,生产具有增强的体积灵活性的更多产品。生产,供应和价值链足迹与当今的单片和集中式批量制造操作无关。临床试验和药品开发成本节省成本,支持更多快速扩大和市场进入模型,并提前参与SC设计师在新产品开发中。需要解决的主要供应链和工业转型挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号